Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Seagen Inc.
National Institutes of Health Clinical Center (CC)
Ohio State University
University Health Network, Toronto
Endeavor Biomedicines, Inc.
National Institutes of Health Clinical Center (CC)
AstraZeneca
Genmab
Nuvectis Pharma, Inc.
National Institutes of Health Clinical Center (CC)
A2 Biotherapeutics Inc.
Zhejiang University
National Institutes of Health Clinical Center (CC)
A2 Biotherapeutics Inc.
University Hospital, Lille
Royal Marsden NHS Foundation Trust
University of Nebraska
PrECOG, LLC.
Takeda
IDEAYA Biosciences
Lumicell, Inc.
Perspective Therapeutics
Seagen Inc.
Dana-Farber Cancer Institute
Novartis
Stanford University
Fundación GECP
H. Lee Moffitt Cancer Center and Research Institute
VM Oncology, LLC
Dana-Farber Cancer Institute
Bristol-Myers Squibb
NeoTX Therapeutics Ltd.
HiFiBiO Therapeutics
Brigham and Women's Hospital
Tango Therapeutics, Inc.
Dana-Farber Cancer Institute
National Institutes of Health Clinical Center (CC)
Ipsen
Brigham and Women's Hospital
Vivace Therapeutics, Inc
Incyte Corporation
Actym Therapeutics, Inc.
Memorial Sloan Kettering Cancer Center
Groupe Francais De Pneumo-Cancerologie
Baylor College of Medicine
Merck Sharp & Dohme LLC
Novartis
Travera Inc